TY - JOUR
T1 - Individualized glycaemic targets and pharmacotherapy in type 2 diabetes
AU - Bailey, Clifford J.
AU - Aschner, Pablo
AU - del Prato, James
AU - LaSalle, James
AU - Ji, Linong
AU - Matthaei, Stephan
PY - 2013/9
Y1 - 2013/9
N2 - The Global Partnership for Effective Diabetes Management, established to provide practical guidance to improve patient outcomes in diabetes, has developed and modified recommendations to improve glycaemic control in type 2 diabetes. The Global Partnership advocates an individualized therapeutic approach and, as part of the process to customize therapy, has previously identified specific type 2 diabetes patient subgroups that require special consideration. This article builds on earlier publications, expanding the scope of practical guidance to include newly diagnosed individuals with complications and women with diabetes in pregnancy. Good glycaemic control remains the cornerstone of managing type 2 diabetes, and plays a vital role in preventing or delaying the onset and progression of diabetic complications. Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes.
AB - The Global Partnership for Effective Diabetes Management, established to provide practical guidance to improve patient outcomes in diabetes, has developed and modified recommendations to improve glycaemic control in type 2 diabetes. The Global Partnership advocates an individualized therapeutic approach and, as part of the process to customize therapy, has previously identified specific type 2 diabetes patient subgroups that require special consideration. This article builds on earlier publications, expanding the scope of practical guidance to include newly diagnosed individuals with complications and women with diabetes in pregnancy. Good glycaemic control remains the cornerstone of managing type 2 diabetes, and plays a vital role in preventing or delaying the onset and progression of diabetic complications. Individualizing therapeutic goals and treatments to meet glycaemic targets safely and without delay remains paramount, in addition to a wider programme of care to reduce cardiovascular risk factors and improve patient outcomes.
KW - glycaemic targets
KW - global partnership
KW - individualized therapy
KW - type 2 diabetes
KW - HbA1c
UR - http://www.scopus.com/inward/record.url?scp=84882323601&partnerID=8YFLogxK
UR - http://dvr.sagepub.com/content/10/5/397
U2 - 10.1177/1479164113490765
DO - 10.1177/1479164113490765
M3 - Article
AN - SCOPUS:84882323601
SN - 1479-1641
VL - 10
SP - 397
EP - 409
JO - Diabetes and Vascular Disease Research
JF - Diabetes and Vascular Disease Research
IS - 5
ER -